M
Mitsuhiko Abe
Researcher at Kurume University
Publications - 34
Citations - 873
Mitsuhiko Abe is an academic researcher from Kurume University. The author has contributed to research in topics: Vascular endothelial growth factor & Cancer. The author has an hindex of 16, co-authored 34 publications receiving 657 citations. Previous affiliations of Mitsuhiko Abe include Karolinska Institutet.
Papers
More filters
Journal ArticleDOI
Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance
Hideki Iwamoto,Hideki Iwamoto,Mitsuhiko Abe,Mitsuhiko Abe,Yunlong Yang,Dongmei Cui,Takahiro Seki,Masaki Nakamura,Kayoko Hosaka,Sharon Lim,Jieyu Wu,Xingkang He,Xiaoting Sun,Xiaoting Sun,Yongtian Lu,Qingjun Zhou,Weiyun Shi,Takuji Torimura,Guohui Nie,Qi Li,Yihai Cao +20 more
TL;DR: An effective cancer therapy concept is proposed by combining drugs that target angiogenesis and lipid metabolism, and genetic and pharmacological loss of CPT1 function sensitizes AAD therapeutic efficacy and enhances its anti-tumor effects.
Journal ArticleDOI
Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
Yunlong Yang,Yin Zhang,Hideki Iwamoto,Kayoko Hosaka,Takahiro Seki,Patrik Andersson,Sharon Lim,Carina Fischer,Masaki Nakamura,Mitsuhiko Abe,Renhai Cao,Peter Vilhelm Skov,Fang Chen,Xiaoyun Chen,Yongtian Lu,Guohui Nie,Yihai Cao,Yihai Cao +17 more
TL;DR: It is shown discontinuation of anti-VEGF treatment creates a time-window of profound structural changes of liver sinusoidal vasculatures, exhibiting hyper-permeability and enlarged open-pore sizes of the fenestrated endothelium and loss of VE-cadherin.
Journal ArticleDOI
Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning.
Takahiro Seki,Kayoko Hosaka,Carina Fischer,Sharon Lim,Patrik Andersson,Mitsuhiko Abe,Hideki Iwamoto,Yanyan Gao,Xinsheng Wang,Guo-Hua Fong,Yihai Cao,Yihai Cao +11 more
TL;DR: The data indicate that targeting of VEGFR1 provides an exciting new opportunity for treatment of obesity and metabolic diseases, such as liver steatosis and type 2 diabetes.
Journal ArticleDOI
High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine
Fumitaka Wada,Hironori Koga,Jun Akiba,Takashi Niizeki,Hideki Iwamoto,Yu Ikezono,Toru Nakamura,Mitsuhiko Abe,Atsutaka Masuda,Takahiko Sakaue,Toshimitsu Tanaka,Tatsuyuki Kakuma,Hirohisa Yano,Takuji Torimura +13 more
TL;DR: The xCT inhibitor SASP augmented ROS‐mediated apoptosis in CDDP‐treated HCC cells, in which the CD44v9‐xCT system functioned, and combination treatment with SASP with CDDP may overcome such drug resistance.
Journal ArticleDOI
Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice.
Kinya Inoue,Takuji Torimura,Toru Nakamura,Hideki Iwamoto,Hiroshi Masuda,Mitsuhiko Abe,Osamu Hashimoto,Hironori Koga,Takato Ueno,Hirohisa Yano,Michio Sata +10 more
TL;DR: The antitumor effects of vandetanib in mice suggest that it is a potentially suitable and safe chemotherapeutic agent for HCCs and upregulated VEGF, TGF-α, and EGF in tumor tissues.